Genome-wide significant or replicating variants from GOLD, NASH CRN/MIGen, and metabolic phenotype analyses.

GOLD: Genetics of Obesity-related Liver Disease; NASH CRN: Nonalcoholic Steatohepatitis Clinical Research Network; MIGen: Myocardial Infarction Genetics Consortium;**from The Global Lipids Genetics, GIANT, MAGIC, and DIAGRAM Consortia; Chr. Chromosome; Pos.: position, build 35; Mb: Megabase; EA: effect allele; EAF: Effect allele frequency; Effect: increase in inverse normalized fatty liver by computed tomography SE: Standard Error;% Var- percentage of variance explained; GOLD P: p-value of association in GOLD;EAFa: Frequency of the effect allele in cases from the NASH CRN study;EAFb: Frequency of the effect allele in controls from the MIGen study; NAFLD: nonalcoholic fatty liver disease; ORNAFLD: odds ratio for the presence of NAFLD on pathology per effect allele; NAFLD P: False discovery rate p-value of association for histologic NAFLD; LDL: low density lipoprotein cholesterol; HDL: high density lipoprotein cholesterol; TG: triglycerides; Glucose: fasting glucose; HOMA-IR: homeostatic model assessment of insulin resistance; P: p-value of association; Dir: direction of effect allele for significant associations in GOLD, NASH CRN/MIGen, LDL, HDL, TG, glucose, HOMA-IR analyses respectively; +/− represents increasing/decreasing fatty liver in GOLD, and having a higher/lower odds of having NAFLD in the NASH CRN/MIGen analyses and higher/lower LDL, HDL, TG, glucose, HOMA-IR respectively; N represents no significant effect; PNPLA3: patatin-like phospholipase domain-containing protein 3 (HUGO Gene Nomenclature Committee, HGNC: 18590); NCAN: neurocan (HGNC: 2465); LYPLAL1: lysophospholipase-like 1 (HGNC: 20440); GCKR: glucokinase regulatory protein (HGNC: 4196); PPP1R3B: protein phosphatase 1, regulatory subunit 3b (HGNC: 14942).